1. An MDM2 inhibitor achieves synergistic cytotoxic effects with adenoviruses lacking E1B55kDa gene on mesothelioma with the wild-type p53 through augmenting NFI expression.
- Author
-
Nguyen TTT, Shingyoji M, Hanazono M, Zhong B, Morinaga T, Tada Y, Shimada H, Hiroshima K, and Tagawa M
- Subjects
- Adenoviridae growth & development, Animals, Apoptosis drug effects, Apoptosis Regulatory Proteins genetics, Apoptosis Regulatory Proteins metabolism, Cell Line, Tumor, Chemotherapy, Adjuvant, Gene Expression Regulation, Neoplastic, Mesothelioma genetics, Mesothelioma metabolism, Mesothelioma virology, Mice, Inbred BALB C, Mice, Nude, Neurofibromin 1 genetics, Oncolytic Viruses growth & development, Proto-Oncogene Proteins c-mdm2 genetics, Proto-Oncogene Proteins c-mdm2 metabolism, Tumor Burden drug effects, Tumor Suppressor Protein p53 genetics, Virus Replication, Xenograft Model Antitumor Assays, Mice, Adenoviridae genetics, Adenovirus E1 Proteins genetics, Antineoplastic Agents pharmacology, Imidazoles pharmacology, Imidazolines pharmacology, Mesothelioma therapy, Neurofibromin 1 metabolism, Oncolytic Virotherapy, Oncolytic Viruses genetics, Piperazines pharmacology, Proto-Oncogene Proteins c-mdm2 antagonists & inhibitors, Tumor Suppressor Protein p53 metabolism
- Abstract
A majority of mesothelioma specimens were defective of p14 and p16 expression due to deletion of the INK4A/ARF region, and the p53 pathway was consequently inactivated by elevated MDM2 functions which facilitated p53 degradaton. We investigated a role of p53 elevation by MDM2 inhibitors, nutlin-3a and RG7112, in cytotoxicity of replication-competent adenoviruses (Ad) lacking the p53-binding E1B55kDa gene (Ad-delE1B). We found that a growth inhibition by p53-activating Ad-delE1B was irrelevant to p53 expression in the infected cells, but combination of Ad-delE1B and the MDM2 inhibitor produced synergistic inhibitory effects on mesothelioma with the wild-type but not mutated p53 genotype. The combination augmented p53 phosphorylation, activated apoptotic but not autophagic pathway, and enhanced DNA damage signals through ATM-Chk2 phosphorylation. The MDM2 inhibitors facilitated production of the Ad progenies through augmented expression of nuclear factor I (NFI), one of the transcriptional factors involved in Ad replications. Knocking down of p53 with siRNA did not increase the progeny production or the NFI expression. We also demonstrated anti-tumor effects by the combination of Ad-delE1B and the MDM2 inhibitors in an orthotopic animal model. These data collectively indicated that upregulation of wild-type p53 expression contributed to cytotoxicity by E1B55kDa-defective replicative Ad through NFI induction and suggested that replication-competent Ad together with augmented p53 levels was a therapeutic strategy for p53 wild-type mesothelioma.
- Published
- 2021
- Full Text
- View/download PDF